Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pulmonary Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pulmonary Other
    MDCT Scans Offer Noninvasive Alternative to Bronchoscopy in Patients With Airway Stent Complications - (DGNews)
    Patients With Pulmonary Arterial Hypertension Who Discontinue Other Medications Due to Liver Abnormalities Fare Well With Ambrisentan: Presented at CHEST - (DGDispatch)
    Tadalafil Effective for Pulmonary Arterial Hypertension: Presented at CHEST - (DGDispatch)
    Ambrisentan Shows Long-Term Efficacy in Treatment of Pulmonary Hypertension: Presented at CHEST - (DGDispatch)
    Dexmedetomidine Reduces Respiratory Depression in Patients Undergoing Monitored Anaesthesia Care: Presented at ASA - (DGDispatch)

    News archive

     Recent webcasts/CME - Pulmonary Other
  • Improving the Standard of Care in Acute Hypertension
  • Management of Pulmonary Hypertension in Connective Tissue Disease
    Silica-Related Lung Disease: It's Still Here

    Webcasts/CME archive

     Recent cases - Pulmonary Other
      Gemcitabine-Induced Pulmonary Toxicity During Adjuvant Therapy in a Patient with Pancreatic Cancer
      Massive Pulmonary Emboli Associated with Olanzapine
      Pneumopericardium
      A Pulmonary Mass with Invasion into the Heart
      Exudative Pleurisy of Coccidioidomycosis: A Case Report and Review of the Literature

      Cases archive
        




      my personal edition > pulmonary other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Radical Decortication/Pleurectomy Best Surgical Approach for N2 Malignant Mesothelioma: Presented at STS

      By Ed Susman

      FORT LAUDERDALE, FL -- February 1, 2008 -- Patients who underwent the more extensive treatment of radical decortication/pleurectomy in attempt to cure stage 3 pure epithelial mesothelioma appear to have significantly better outcomes than patients who had less extensive operations, according to a study presented here at the Society of Thoracic Surgeons 44th Annual Meeting (STS).

      "There is no gold standard surgical procedure in stage 3 mesothelioma," said Delphine Trousse, MD, Registrar in Thoracic Surgery, Hôpital Sainte Marguerite, Marseille, France, in a presentation on January 29.

      However, in reviewing 127 consecutive cases of patients who presented with stage 3 mesothelioma, Dr. Trousse found that the 57 patients who underwent radical decortication/pleurectomy had better overall survival at 1 year (83%) and at 2 years (73%) than did patients treated with alternative surgical techniques.

      One-year survival among the 35 patients treated by extrapleural pneumonectomy was 55% and 2-year survival was 18%. One-year survival for 35 patients who were treated by vascular access thorosectomy (VATS) decortication/pleurectomy was 67% and 2-year survival was 22%.

      The difference between the extensive surgery and the less extensive treatments reached statistical significance at the P =.003 level.

      Dr. Trousse's oral presentation reported used data from Glenfield Hospital, Leicester, England, United Kingdom, where she conducted her research before relocating to Marseille, France.

      "These data support the preferential choice of radical pleurectomy/decortication in surgery for N2 positive epithelial mesothelioma," she said.

      She noted that 90-day survival in the series was best among patients who underwent VATS pleurectomy/decortication (P =.024). VATS surgery was reserved for patients who were either too frail or had comorbidities that made them unfit for the more extensive surgical procedures.

      "Long-term survival was not associated with sex, age," she said. There were 104 men and 23 women in the series; the average age of the patients undergoing surgery was 62 years.

      "Median survival for the whole group was 50 months, with 1-year survival of 63%, 38% at 2 years and 14% at 3 years, which is pretty good survival for stage 3 mesothelioma," Dr. Trousse said.


      [Presentation title: Which is the Best Surgical Approach for N2 Positive Epithelial Malignant Mesothelioma? Long-Term Outcome After Extrapleural Pneumonectomy Versus Radical and VATS Decortication/Pleurectomy. Abstract 42]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send